Cargando…
VERDICT MRI for Prostate Cancer: Intracellular Volume Fraction versus Apparent Diffusion Coefficient
BACKGROUND: Biologic specificity of diffusion MRI in relation to prostate cancer aggressiveness may improve by examining separate components of the diffusion MRI signal. The Vascular, Extracellular, and Restricted Diffusion for Cytometry in Tumors (VERDICT) model estimates three distinct signal comp...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Radiological Society of North America
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6493214/ https://www.ncbi.nlm.nih.gov/pubmed/30938627 http://dx.doi.org/10.1148/radiol.2019181749 |
_version_ | 1783415174868238336 |
---|---|
author | Johnston, Edward W. Bonet-Carne, Elisenda Ferizi, Uran Yvernault, Ben Pye, Hayley Patel, Dominic Clemente, Joey Piga, Wivijin Heavey, Susan Sidhu, Harbir S. Giganti, Francesco O’Callaghan, James Brizmohun Appayya, Mrishta Grey, Alistair Saborowska, Alexandra Ourselin, Sebastien Hawkes, David Moore, Caroline M. Emberton, Mark Ahmed, Hashim U. Whitaker, Hayley Rodriguez-Justo, Manuel Freeman, Alexander Atkinson, David Alexander, Daniel Panagiotaki, Eleftheria Punwani, Shonit |
author_facet | Johnston, Edward W. Bonet-Carne, Elisenda Ferizi, Uran Yvernault, Ben Pye, Hayley Patel, Dominic Clemente, Joey Piga, Wivijin Heavey, Susan Sidhu, Harbir S. Giganti, Francesco O’Callaghan, James Brizmohun Appayya, Mrishta Grey, Alistair Saborowska, Alexandra Ourselin, Sebastien Hawkes, David Moore, Caroline M. Emberton, Mark Ahmed, Hashim U. Whitaker, Hayley Rodriguez-Justo, Manuel Freeman, Alexander Atkinson, David Alexander, Daniel Panagiotaki, Eleftheria Punwani, Shonit |
author_sort | Johnston, Edward W. |
collection | PubMed |
description | BACKGROUND: Biologic specificity of diffusion MRI in relation to prostate cancer aggressiveness may improve by examining separate components of the diffusion MRI signal. The Vascular, Extracellular, and Restricted Diffusion for Cytometry in Tumors (VERDICT) model estimates three distinct signal components and associates them to (a) intracellular water, (b) water in the extracellular extravascular space, and (c) water in the microvasculature. PURPOSE: To evaluate the repeatability, image quality, and diagnostic utility of intracellular volume fraction (FIC) maps obtained with VERDICT prostate MRI and to compare those maps with apparent diffusion coefficient (ADC) maps for Gleason grade differentiation. MATERIALS AND METHODS: Seventy men (median age, 62.2 years; range, 49.5–82.0 years) suspected of having prostate cancer or undergoing active surveillance were recruited to a prospective study between April 2016 and October 2017. All men underwent multiparametric prostate and VERDICT MRI. Forty-two of the 70 men (median age, 67.7 years; range, 50.0–82.0 years) underwent two VERDICT MRI acquisitions to assess repeatability of FIC measurements obtained with VERDICT MRI. Repeatability was measured with use of intraclass correlation coefficients (ICCs). The image quality of FIC and ADC maps was independently evaluated by two board-certified radiologists. Forty-two men (median age, 64.8 years; range, 49.5–79.6 years) underwent targeted biopsy, which enabled comparison of FIC and ADC metrics in the differentiation between Gleason grades. RESULTS: VERDICT MRI FIC demonstrated ICCs of 0.87–0.95. There was no significant difference between image quality of ADC and FIC maps (score, 3.1 vs 3.3, respectively; P = .90). FIC was higher in lesions with a Gleason grade of at least 3+4 compared with benign and/or Gleason grade 3+3 lesions (mean, 0.49 ± 0.17 vs 0.31 ± 0.12, respectively; P = .002). The difference in ADC between these groups did not reach statistical significance (mean, 1.42 vs 1.16 × 10(-3) mm(2)/sec; P = .26). CONCLUSION: Fractional intracellular volume demonstrates high repeatability and image quality and enables better differentiation of a Gleason 4 component cancer from benign and/or Gleason 3+3 histology than apparent diffusion coefficient. Published under a CC BY 4.0 license. Online supplemental material is available for this article. See also the editorial by Sigmund and Rosenkrantz in this issue. |
format | Online Article Text |
id | pubmed-6493214 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Radiological Society of North America |
record_format | MEDLINE/PubMed |
spelling | pubmed-64932142020-01-28 VERDICT MRI for Prostate Cancer: Intracellular Volume Fraction versus Apparent Diffusion Coefficient Johnston, Edward W. Bonet-Carne, Elisenda Ferizi, Uran Yvernault, Ben Pye, Hayley Patel, Dominic Clemente, Joey Piga, Wivijin Heavey, Susan Sidhu, Harbir S. Giganti, Francesco O’Callaghan, James Brizmohun Appayya, Mrishta Grey, Alistair Saborowska, Alexandra Ourselin, Sebastien Hawkes, David Moore, Caroline M. Emberton, Mark Ahmed, Hashim U. Whitaker, Hayley Rodriguez-Justo, Manuel Freeman, Alexander Atkinson, David Alexander, Daniel Panagiotaki, Eleftheria Punwani, Shonit Radiology Original Research BACKGROUND: Biologic specificity of diffusion MRI in relation to prostate cancer aggressiveness may improve by examining separate components of the diffusion MRI signal. The Vascular, Extracellular, and Restricted Diffusion for Cytometry in Tumors (VERDICT) model estimates three distinct signal components and associates them to (a) intracellular water, (b) water in the extracellular extravascular space, and (c) water in the microvasculature. PURPOSE: To evaluate the repeatability, image quality, and diagnostic utility of intracellular volume fraction (FIC) maps obtained with VERDICT prostate MRI and to compare those maps with apparent diffusion coefficient (ADC) maps for Gleason grade differentiation. MATERIALS AND METHODS: Seventy men (median age, 62.2 years; range, 49.5–82.0 years) suspected of having prostate cancer or undergoing active surveillance were recruited to a prospective study between April 2016 and October 2017. All men underwent multiparametric prostate and VERDICT MRI. Forty-two of the 70 men (median age, 67.7 years; range, 50.0–82.0 years) underwent two VERDICT MRI acquisitions to assess repeatability of FIC measurements obtained with VERDICT MRI. Repeatability was measured with use of intraclass correlation coefficients (ICCs). The image quality of FIC and ADC maps was independently evaluated by two board-certified radiologists. Forty-two men (median age, 64.8 years; range, 49.5–79.6 years) underwent targeted biopsy, which enabled comparison of FIC and ADC metrics in the differentiation between Gleason grades. RESULTS: VERDICT MRI FIC demonstrated ICCs of 0.87–0.95. There was no significant difference between image quality of ADC and FIC maps (score, 3.1 vs 3.3, respectively; P = .90). FIC was higher in lesions with a Gleason grade of at least 3+4 compared with benign and/or Gleason grade 3+3 lesions (mean, 0.49 ± 0.17 vs 0.31 ± 0.12, respectively; P = .002). The difference in ADC between these groups did not reach statistical significance (mean, 1.42 vs 1.16 × 10(-3) mm(2)/sec; P = .26). CONCLUSION: Fractional intracellular volume demonstrates high repeatability and image quality and enables better differentiation of a Gleason 4 component cancer from benign and/or Gleason 3+3 histology than apparent diffusion coefficient. Published under a CC BY 4.0 license. Online supplemental material is available for this article. See also the editorial by Sigmund and Rosenkrantz in this issue. Radiological Society of North America 2019-05 2019-04-02 /pmc/articles/PMC6493214/ /pubmed/30938627 http://dx.doi.org/10.1148/radiol.2019181749 Text en 2019 by the Radiological Society of North America, Inc. http://creativecommons.org/licenses/by/4.0/ Published under a (http://creativecommons.org/licenses/by/4.0/) CC BY 4.0 license. |
spellingShingle | Original Research Johnston, Edward W. Bonet-Carne, Elisenda Ferizi, Uran Yvernault, Ben Pye, Hayley Patel, Dominic Clemente, Joey Piga, Wivijin Heavey, Susan Sidhu, Harbir S. Giganti, Francesco O’Callaghan, James Brizmohun Appayya, Mrishta Grey, Alistair Saborowska, Alexandra Ourselin, Sebastien Hawkes, David Moore, Caroline M. Emberton, Mark Ahmed, Hashim U. Whitaker, Hayley Rodriguez-Justo, Manuel Freeman, Alexander Atkinson, David Alexander, Daniel Panagiotaki, Eleftheria Punwani, Shonit VERDICT MRI for Prostate Cancer: Intracellular Volume Fraction versus Apparent Diffusion Coefficient |
title | VERDICT MRI for Prostate Cancer: Intracellular Volume Fraction versus
Apparent Diffusion Coefficient |
title_full | VERDICT MRI for Prostate Cancer: Intracellular Volume Fraction versus
Apparent Diffusion Coefficient |
title_fullStr | VERDICT MRI for Prostate Cancer: Intracellular Volume Fraction versus
Apparent Diffusion Coefficient |
title_full_unstemmed | VERDICT MRI for Prostate Cancer: Intracellular Volume Fraction versus
Apparent Diffusion Coefficient |
title_short | VERDICT MRI for Prostate Cancer: Intracellular Volume Fraction versus
Apparent Diffusion Coefficient |
title_sort | verdict mri for prostate cancer: intracellular volume fraction versus
apparent diffusion coefficient |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6493214/ https://www.ncbi.nlm.nih.gov/pubmed/30938627 http://dx.doi.org/10.1148/radiol.2019181749 |
work_keys_str_mv | AT johnstonedwardw verdictmriforprostatecancerintracellularvolumefractionversusapparentdiffusioncoefficient AT bonetcarneelisenda verdictmriforprostatecancerintracellularvolumefractionversusapparentdiffusioncoefficient AT feriziuran verdictmriforprostatecancerintracellularvolumefractionversusapparentdiffusioncoefficient AT yvernaultben verdictmriforprostatecancerintracellularvolumefractionversusapparentdiffusioncoefficient AT pyehayley verdictmriforprostatecancerintracellularvolumefractionversusapparentdiffusioncoefficient AT pateldominic verdictmriforprostatecancerintracellularvolumefractionversusapparentdiffusioncoefficient AT clementejoey verdictmriforprostatecancerintracellularvolumefractionversusapparentdiffusioncoefficient AT pigawivijin verdictmriforprostatecancerintracellularvolumefractionversusapparentdiffusioncoefficient AT heaveysusan verdictmriforprostatecancerintracellularvolumefractionversusapparentdiffusioncoefficient AT sidhuharbirs verdictmriforprostatecancerintracellularvolumefractionversusapparentdiffusioncoefficient AT gigantifrancesco verdictmriforprostatecancerintracellularvolumefractionversusapparentdiffusioncoefficient AT ocallaghanjames verdictmriforprostatecancerintracellularvolumefractionversusapparentdiffusioncoefficient AT brizmohunappayyamrishta verdictmriforprostatecancerintracellularvolumefractionversusapparentdiffusioncoefficient AT greyalistair verdictmriforprostatecancerintracellularvolumefractionversusapparentdiffusioncoefficient AT saborowskaalexandra verdictmriforprostatecancerintracellularvolumefractionversusapparentdiffusioncoefficient AT ourselinsebastien verdictmriforprostatecancerintracellularvolumefractionversusapparentdiffusioncoefficient AT hawkesdavid verdictmriforprostatecancerintracellularvolumefractionversusapparentdiffusioncoefficient AT moorecarolinem verdictmriforprostatecancerintracellularvolumefractionversusapparentdiffusioncoefficient AT embertonmark verdictmriforprostatecancerintracellularvolumefractionversusapparentdiffusioncoefficient AT ahmedhashimu verdictmriforprostatecancerintracellularvolumefractionversusapparentdiffusioncoefficient AT whitakerhayley verdictmriforprostatecancerintracellularvolumefractionversusapparentdiffusioncoefficient AT rodriguezjustomanuel verdictmriforprostatecancerintracellularvolumefractionversusapparentdiffusioncoefficient AT freemanalexander verdictmriforprostatecancerintracellularvolumefractionversusapparentdiffusioncoefficient AT atkinsondavid verdictmriforprostatecancerintracellularvolumefractionversusapparentdiffusioncoefficient AT alexanderdaniel verdictmriforprostatecancerintracellularvolumefractionversusapparentdiffusioncoefficient AT panagiotakieleftheria verdictmriforprostatecancerintracellularvolumefractionversusapparentdiffusioncoefficient AT punwanishonit verdictmriforprostatecancerintracellularvolumefractionversusapparentdiffusioncoefficient |